Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) said CEO Laxminarayan Bhat, PhD, will join a Key Opinion Leader webinar and fireside chat hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The session will include KOLs Dr. Larry Ereshefsky and Dr. Mark Opler, focus on the unmet need and treatment landscape for schizophrenia, and discuss phase 3 clinical data for Reviva’s lead candidate brilaroxazine. The conversation will be moderated by James Molloy of A.G.P. A replay will be posted in Reviva’s investor relations section after the event.
Positive
- None.
Negative
- None.
News Market Reaction 42 Alerts
On the day this news was published, RVPH gained 25.50%, reflecting a significant positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -34.0% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $81M at that time. Trading volume was very high at 4.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners' James Molloy.
To register for the event, please click here. A replay of the webinar will be accessible in the investors section of Reviva’s website following the event.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Reviva (RVPH) presenting in the A.G.P. webinar?
What topics will Reviva (RVPH) cover in the October 10, 2025 webinar?
Who are the key speakers alongside Reviva (RVPH) CEO in the webinar?
How can investors register for the Reviva (RVPH) webinar on October 10, 2025?
Will there be a replay of the Reviva (RVPH) KOL webinar if I miss the live session?
Will the Reviva (RVPH) webinar include details on brilaroxazine phase 3 results?
